Helus Pharma CEO Will Discuss Neuropsychiatry on September 23
CEO Michael Halstead is set to participate in a virtual fireside chat at an industry summit this Wednesday.
Updated on Sept. 21, 2026 in Mental Health
Helus Pharma CEO Michael Halstead will join a fireside chat on September 23, 2026, to discuss the firm's progress in neuropsychiatry. The event will take place via a live webcast during the summit.
Why it matters
The discussion focuses on the company's efforts to develop novel serotonergic agonists designed to address significant unmet medical needs in the treatment of depression and anxiety.
Helus Pharma is currently advancing HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company manages clinical research programs across Canada, the U.S., the U.K., and Ireland.
The players
Michael Halstead
He serves as the CEO of Helus Pharma and will lead a discussion on neuropsychiatric advancements.
Helus Pharma
The company develops synthetic molecules to activate serotonin pathways for treating anxiety and depression.
U.S. Food and Drug Administration
This federal agency granted Breakthrough Therapy Designation to the company's clinical candidate HLP003.
The details
Helus Pharma utilizes synthetic molecules to activate serotonin pathways as a primary method for its psychiatric drug development. Michael Halstead will provide updates on the company's pipeline during the 6th annual neuropsychiatry summit.
Timeline
September 23, 2026: CEO Michael Halstead will participate in a fireside chat at 9:00 a.m. EDT.
Deeper Dive
The company's developmental focus follows a pattern set by the FDA Breakthrough Therapy Designation to expedite drug development for serious conditions.
Patients seeking alternatives for depression and anxiety may benefit from the ongoing clinical progress of the firm's serotonergic agonist treatments. The company's expansion into global clinical trials could eventually increase future access to these specialized therapies.
The takeaway
The event highlights how specialized pharmaceutical companies are utilizing serotonin pathways to target complex mental health conditions. Investors and clinicians can look for future updates on the Phase 3 clinical data for the company's leading therapeutic candidate.
Further reading
For more information on the current landscape of psychiatric research, visit Mental Health.
